Weight problems Medication Put These Shares on a Crash Food plan—Now They’re Rebounding

There’s a little bit of cognitive dissonance in healthcare investing proper now.

After reviewing the extremely anticipated outcomes from a research of Novo Nordisk’s blockbuster weight problems therapy Wegovy launched over the weekend, cardiologists at a serious medical assembly and the pharma crowd on Wall Road had been broadly upbeat. “Immediately’s confirmatory outcomes lay the groundwork for the approaching paradigm shift of metabolic therapy,” gushed Evan Seigerman, an analyst at BMO Capital Markets.